Japanese pharma Astellas has culled a muscle disease research pact with Cytokinetics two years after a partnered med between the two flopped in a midstage test.
Through a Securities and Exchange Commission filing, Californian biotech Cytokinetics said Astellas had decided to walk away from the deal, extended last year into this, for skeletal sarcomere activators to help in conditions that stop normal muscle contraction.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,